^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Tasfygo (tasurgratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1414 - Effect of E7090, an FGFR1-3 selective inhibitor, on resistance to a CDK4/6 inhibitor and endocrine therapy in ER(+)/HER2(-) breast cancer preclinical models
Published date:
03/10/2021
Excerpt:
...E7090 shows antitumor activity against ER(+)/HER2(-) BC with prior a CDK4/6 inhibitor and/or ET.
